Johnson & Johnson has selected Onco360 as pharmacy partner for the distribution of LAZCLUZE (lazertinib).

The medication is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, recently approved for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations.

Its approval, along with that of RYBREVANT (amivantamab-vmjw), is said to offer a chemotherapy-free regimen for patients whose tumours have EGFR exon 19 deletions or exon 21 L858R mutations.

Clinical studies have demonstrated that this new treatment regimen provides superior progression-free survival compared to the traditional standard of care.

Manufactured by Janssen Biotech, a division of Johnson & Johnson, LAZCLUZE has received FDA approval based on positive outcomes from the Phase III MARIPOSA study.

The study indicated that the combination of RYBREVANT and LAZCLUZE reduced the risk of disease progression or death by 30% compared to osimertinib.

Patients experienced a nine-month longer median duration of response.

The median progression-free survival (PFS) for patients treated with the combination of RYBREVANT and LAZCLUZE was significantly extended, reaching 23.7 months, as opposed to 16.6 months for those treated with osimertinib.

Onco360 chief commercial officer Benito Fernandez stated: “Onco360 is grateful for the opportunity to partner with the Johnson and Johnson team and become a speciality pharmacy provider for LAZCLUZE.”

“We are proud to add this first-line, chemotherapy-free, targeted therapy to our portfolio to treat patients with locally advanced or metastatic EGFR-mutation non-small cell lung cancer.”